INCY DMA
As of date:8/13/2020
INCY stock price:95.56
INCY 50 DMA:100.52
INCY 200 DMA:89.23
INCY MACD (200-50):-11.29

Also see:
INCY Market Cap History
INCY Shares Outstanding History
INCY YTD Return
INCY RSI
INCY MACD
INCY Technical Analysis

CPAA Crosses Below Key Moving Average Level
41 minutes ago


iQIYI (IQ) Shares Cross Below 200 DMA
1 hour, 17 minutes ago


Kulicke & Soffa Industries Breaks Below 200-Day Moving Average - Notable for KLIC
1 hour, 30 minutes ago


Vericel Breaks Below 200-Day Moving Average - Notable for VCEL
1 hour, 30 minutes ago


Notable Two Hundred Day Moving Average Cross - IGHG
1 hour, 48 minutes ago


PURE Storage Breaks Below 200-Day Moving Average - Notable for PSTG
3 hours, 16 minutes ago


BioDelivery Sciences International (BDSI) Shares Cross Above 200 DMA
3 hours, 16 minutes ago


Garrett Motion (GTX) Shares Cross Above 200 DMA
3 hours, 17 minutes ago


GameStop (GME) Shares Cross Above 200 DMA
3 hours, 19 minutes ago


Transcat Breaks Above 200-Day Moving Average - Bullish for TRNS
Thursday, August 13, 5:42 PM


SY Crosses Below Key Moving Average Level
Thursday, August 13, 5:41 PM


HNI Crosses Below Key Moving Average Level
Thursday, August 13, 5:39 PM


Bullish Two Hundred Day Moving Average Cross - PLAN
Thursday, August 13, 5:39 PM


CRH.CA Crosses Above Key Moving Average Level
Thursday, August 13, 3:45 PM


CHSCN Makes Bullish Cross Above Critical Moving Average
Thursday, August 13, 11:32 AM


More Technical Analysis News

INCY DMAINCY MACD
Incyte is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. JAKAFI (ruxolitinib) has been approved for the treatment of patients with intermediate or high-risk myelofibrosis, for the treatment of patients with polycythemia vera, and for the treatment of steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and older. Co. has also obtained a license to develop and commercialize ICLUSIG (ponatinib) in Europe and other select countries. In the European Union, ICLUSIG is approved for the treatment of adult patients with chronic phase, accelerated phase or blast phase chronic myeloid leukemia.

When researching a stock like Incyte, many investors are the most familiar with Fundamental Analysis — looking at a company's balance sheet, earnings, revenues, and what's happening in that company's underlying business. Investors who use Fundamental Analysis to identify good stocks to buy or sell can also benefit from INCY Technical Analysis to help find a good entry or exit point. Technical Analysis is blind to the fundamentals and looks only at the trading data for INCY stock — the real life supply and demand for the stock over time — and examines that data in different ways. One of those ways is to calculate a Simpe Moving Average ("SMA") by looking back a certain number of days. One of the most popular "longer look-backs" is the INCY 200 day moving average ("INCY 200 DMA"), while one of the most popular "shorter look-backs" is the INCY 50 day moving average ("INCY 50 DMA"). A chart showing both of these popular moving averages is shown on this page for Incyte.
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks

10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
Quotes delayed 20 minutes
Get Free SEC filing alerts for INCY:
INCY SEC Filing Email Alerts ServiceExternal link
Video: Technical Analysis


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Incyte (INCY) is categorized under the Healthcare sector; to help you further research DMA, below are some other companies in the same sector:

IQV DMA
ISRG DMA
JNJ DMA
LH DMA
LLY DMA
MCK DMA
MDT DMA
MMM DMA
MRK DMA
MYL DMA
More Healthcare companies »

 

INCY DMA | www.StockDMA.com | Copyright © 2019 - 2020, All Rights Reserved

Nothing in StockDMA.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.